Market Size and Forecast Market Size in 2025: USD 60.6 Billion Market Size by 2035: USD 307 Billion CAGR: 17.61% from 2026 to 2035 Base Year: 2025 Forecast Period: 2026-2035 Historical Data: 2022-2024 To Get more information on GLP-1 Receptor Agonist Market - Request Free Sample Report GLP-1 Receptor Agonist Market Trends Oral GLP-1 formulations led by Novo Nordisk's Rybelsus and Eli Lilly's orforglipron in development are expanding the patient population who will accept GLP-1 therapy by removing the injection barrier that constrains current market penetration
Examples: whole grains, legumes, produce such as apples, oranges, and asparagus, and chia or flax seeds
For oral NAD+, bioavailability appears to be extremely low, with most of the molecule being degraded before absorption or converted to smaller metabolites during the digestive process
What are GLP-1 agonists
Over the next two decades, formulations evolved toward longer-acting, once-weekly injections with greater potency
Frequency and risk factors of gout flares in a large population-based cohort of incident gout
